Biomanufacturing Summit Details
Important Dates: Please mark your calendars. We look forward to meeting you at the summit.
- May 22-23, 2017: Summit on “Beyond mAbs”
- May 24-26, 2017: Training on Advanced Industrial Bioprocessing
Location: UMass Club, 1 Beacon Street, Boston, Mass.
Theme: Beyond Monoclonal Antibodies
- Session 1: Cell therapeutic Dev. and Manufacturing – Advances and Challenges
- Session 2: Regulatory Sciences, Standardization and Workforce Development
- Session 3: Protein therapeutics Dev. and Manufacturing – Advances and Challenges
- Session 4: Gene therapeutics Dev. and Manufacturing – Advances and Challenges
In addition, the following area of interest will be discussed:
- Emerging Technology and New Therapeutics
- Regulatory Sciences and Standardization
- Industry Practices and New Trends in PAT, QbD, Quality Metrics, and Process Validation
- Integrated Continuous Manufacturing
- Systems, Synthetic Biology in Biomanufacturing
Featured Speakers
Plenary Speakers
- Morrey Atkinson, Ph.D., VP of Biologics Development, BMS
- Lucinda Buhse, Ph.D., Director of OTR, OPQ / CDER / FDA
Session Speakers
- Julie Murrell, Head, Cell Therapy Bioprocessing, MilliporeSigma
- Caroline Dugopolski, VP, Technical Operations, Histogenics
- Karen Nichols, Chief Regulatory Officer, ISCT
- Yu-Kyeong Hwang, R&D Head, Green Cross LabCell
- Kelvin Lee, Professor, NIIMBL Director, University of Delaware
- Sean Bermingham, VP, Life Sciences and Prinipal Consultant, PSE Enterprise Inc.
- Mark Bruso, Manager, Labor Market Reearch, Massbio
- Tom Bollenback, Chief Technology Officer, Advanced Regenerative Manufacturing Institute
- Cyrus Agarabi, Regulatory Research Officer, OBP / FDA/ CDER/DBR II
- Armin Opitz, Sr. Process Engineer, Sanofi
- Palani Palaniappan, Head, Biologics & New Modalities Development, Pharmaceutical Sciences,Takeda
- Joseph Shiloach, Director, Biotechnology Core Laboratory, NIDDK / NIH
- Roger Hart, Scientific Director, Drug Substance Process Development, Amgen
- Dr. Mark Klempner, Executive Vice-Chancellor, MassBiologics & Professor,UMass Medical School
- Ying Jing, Sr. Director of Cell-line and Cell Culture, Dimensiontx
- Paul Fleming, Sr. Project Manager, Lonza Biologics
- Michael McCaman, VP, Process Sciences, Intellia Therapeutics
- David Dismuke, Director, Vector Production, Voyager Therapeutics, Inc